“It’s reassuring that the CRL confirms the stability and clinical data of Dasynoc. As the review of our New Drug Application continues, we will work together with FDA and our third-party production facility in order to ensure a swift handling of the outstanding questions. As we further review and evaluate, we will announce up-dates if and when we see any deviations from our previously communicated plans,” comments Xspray Pharma CEO Per Andersson.

On July 10, Xspray Pharma received a Complete Response Letter (“CRL”) relating to its Dasynoc New Drug Application (“NDA”) for all six strengths (15 mg, 36 mg, 50 mg, 57 mg, 70 mg, and 100 mg) under review by FDA. In the CRL, the agency noted that the agency received Xspray’s amendment filed on January 10, 2023, which was a complete response to FDA’s prior action letter issued September 1, 2022.
 
In the CRL, the FDA accepted Xspray’s proposed product name, Dasynoc, and did not identify any deficiencies with the stability or clinical data submitted in support of the NDA to date. The FDA, however, did request that Xspray provide additional information to doctors and users to avoid confusion about the proper dosing of Dasynoc.
 
Patient safety is always a primary concern for Xspray, which developed Dasynoc to have no interference when used with PPIs. Whereas, the label for Bristol-Myers Squibbs’s Sprycel® instructs that Sprycel® should not be administered with H2 antagonists or proton pump inhibitors. Xspray will compile the requested information to mitigate any risk of dosing confusion. In light of this, the FDA’s review of the Dasynoc label remains ongoing. The CRL also informed Xspray that the inspection and review of a third-party manufacturing facility is ongoing, and the CRL also requested that Xspray provide additional information in support of its NDA. Xspray will promptly compile all the information requested by FDA.